UNSPSC 85818918: Transfusion of nonautologous antihemophilic factors into central vein, percutaneous approach

This classification denotes the group of activities that yields a surgical intervention or procedure to transfusion of nonautologous antihemophilic factors into central vein, percutaneous approach. This surgical intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 30243V1

UNSPSC 85818918 Transfusion of nonautologous antihemophilic factors into central vein, percutaneous approach is a Commodity code with minimal alignment between its clinical specificity and the recent state and local solicitations tagged under it. The code's nominal scope describes a highly specialized medical procedure—intravenous antihemophilic factor infusion—yet the recent opportunities posted against this code instead cover occupational medical surveillance, disability medical evaluations, pharmacy benefit management, temporary health professional staffing, surgical carve-out networks, and emergency youth detention medical services. None of these activities involve antihemophilic factor transfusion or the vascular access procedures the code describes. The mismatch suggests either systematic miscoding by issuing bodies or use of this code as a catchall for medical services procurement where more precise taxonomy does not fit local procurement practice.

The geographic spread of recent activity includes Arizona (City of Phoenix), California (City of Long Beach and County of Santa Clara), Washington State (Washington State Department of Transportation), Florida (Collier County), and Texas (Harris County). No single jurisdiction or state dominates the recent record. Given the absence of opportunities that actually involve the procedure named in the code, this Commodity code shows little relevant recent activity for firms focused on antihemophilic factor supply, clinical laboratory services, hospital pharmacy procurement, or hemophilia treatment programs at the state and local level.